# Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

> **NCT04646759** · PHASE3 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 516 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Fulvestrant combined with Pyrotinib
- **DRUG:** Capecitabine combined with Pyrotinib

## Key facts

- **NCT ID:** NCT04646759
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-14
- **Primary completion:** 2028-12-14
- **Final completion:** 2030-12-14
- **Target enrollment:** 516 (ESTIMATED)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04646759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04646759, "Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04646759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*